McGuireWoods partner Geoff Cockrell sat down with life‑sciences specialist Amy Cassalia to dissect the post‑closing phase of biotech transactions. Their dialogue zeroed in on how contingent consideration shapes deal economics once signatures are filed. Investors and acquirers alike grapple with the timing, valuation and reporting of these deferred payouts. The nuance matters because deferred obligations can alter reported earnings and influence covenant compliance for publicly traded acquirers.

Cassalia explained that high‑level use of contingent payments stems from regulatory uncertainty and product‑development risk. When outcomes diverge, the contract term commercially reasonable often becomes the focal point of litigation, forcing parties to interpret performance benchmarks. That clause can swing final payouts by millions, reshaping risk allocation for both sellers and financing banks. Such disputes often trigger escrow releases or arbitration, adding layers of cost and timing uncertainty.

The conversation highlighted a surge in earn‑outs, now a staple in life‑sciences M&A as buyers seek leverage while sellers chase upside tied to commercial success. Market participants monitor these structures closely because they affect valuation multiples and post‑deal integration plans. In practice, earn‑outs are forcing buyers to budget for contingent cash outflows well beyond the closing date. Consequently, private equity firms are adjusting their bid models to embed higher downside buffers.